BlackRock
ELDN icon

BlackRock’s Eledon Pharmaceuticals ELDN Stock Holding History

BlackRock’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.5M Buy
4,382,245
+755,037
+21% +$1.78M ﹤0.01% 3311
2025
Q4 		$5.48M Buy
3,627,208
+162,126
+5% +$385K ﹤0.01% 3804
2025
Q3 		$8.97M Buy
3,465,082
+210,930
+6% +$617K ﹤0.01% 3506
2025
Q2 		$8.82M Buy
3,254,152
+2,601,531
+399% +$7.81M ﹤0.01% 3473
2025
Q1 		$2.21M Buy
652,621
+34,997
+6% +$144K ﹤0.01% 3962
2024
Q4 		$2.54M Buy
617,624
+401,756
+186% +$1.58M ﹤0.01% 3968
2024
Q3 		$538K Buy
215,868
+60,788
+39% +$163K ﹤0.01% 4308
2024
Q2 		$409K Buy
155,080
+128,249
+478% +$306K ﹤0.01% 4397
2024
Q1 		$55.3K Sell
26,831
-1,471
-5% -$2.63K ﹤0.01% 4851
2023
Q4 		$50.9K Hold
28,302
– – ﹤0.01% 4963
2023
Q3 		$38.8K Hold
28,302
– – ﹤0.01% 5046
2023
Q2 		$38.8K Sell
28,302
-24,266
-46% -$50.6K ﹤0.01% 5109
2023
Q1 		$124K Buy
52,568
+798
+2% +$2.14K ﹤0.01% 4908
2022
Q4 		$118K Buy
51,770
+2,405
+5% +$5.94K ﹤0.01% 4989
2022
Q3 		$136K Buy
49,365
+1,074
+2% +$3.42K ﹤0.01% 5082
2022
Q2 		$118K Sell
48,291
-11,256
-19% -$34.3K ﹤0.01% 5190
2022
Q1 		$235K Sell
59,547
-3,619
-6% -$14K ﹤0.01% 5066
2021
Q4 		$279K Buy
63,166
+15,658
+33% +$79.2K ﹤0.01% 5030
2021
Q3 		$293K Buy
47,508
+1,214
+3% +$8.49K ﹤0.01% 4891
2021
Q2 		$366K Buy
46,294
+34,012
+277% +$321K ﹤0.01% 4767
2021
Q1 		$131K Buy
12,282
+1,568
+15% +$23.7K ﹤0.01% 4805
2020
Q4 		$165K Buy
10,714
+10,357
+2,901% +$198K ﹤0.01% 4502
2020
Q3 		$6K Hold
357
– – ﹤0.01% 4836
2020
Q2 		$3K Sell
357
-1,344
-79% -$15.2K ﹤0.01% 4872
2020
Q1 		$12K Sell
1,701
-67
-4% -$640 ﹤0.01% 4683
2019
Q4 		$19K Sell
1,768
-14
-0.8% -$148 ﹤0.01% 4665
2019
Q3 		$20K Sell
1,782
-82
-4% -$1.18K ﹤0.01% 4648
2019
Q2 		$34K Buy
1,864
+763
+69% +$33.4K ﹤0.01% 4631
2019
Q1 		$80K Sell
1,101
-52
-5% -$3.45K ﹤0.01% 4407
2018
Q4 		$33K Sell
1,153
-14
-1% -$893 ﹤0.01% 4528
2018
Q3 		$98K Buy
1,167
+33
+3% +$3.37K ﹤0.01% 4458
2018
Q2 		$143K Buy
1,134
+259
+30% +$26.8K ﹤0.01% 4387
2018
Q1 		$80K Sell
875
-18
-2% -$1.33K ﹤0.01% 4375
2017
Q4 		$66K Buy
893
+21
+2% +$1.59K ﹤0.01% 4395
2017
Q3 		$82K Sell
872
-30
-3% -$2.49K ﹤0.01% 4400
2017
Q2 		$95K Sell
902
-2,261
-71% -$230K ﹤0.01% 4413
2017
Q1 		$427K Buy
3,163
+3,160
+105,333% +$464K ﹤0.01% 4007
2016
Q4 		$0 Sell
3
-1
-25% -$192 ﹤0.01% 3751
2016
Q3 		$1K Hold
4
– – ﹤0.01% 3639
2016
Q2 		$3K Buy
4
+2
+100% +$2.21K ﹤0.01% 3572
2016
Q1 		$2K Buy
2
+1
+100% +$982 ﹤0.01% 3449
2015
Q4 		$2K Hold
1
– – ﹤0.01% 3308
2015
Q3 		$2K Hold
1
– – ﹤0.01% 3162
2015
Q2 		$3K Hold
1
– – ﹤0.01% 3185
2015
Q1 		$2K Buy
+1
New +$2.21K ﹤0.01% 3127

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
ZP
Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock's ELDN Position: Q1 2026 in Review

BlackRock increased its Eledon Pharmaceuticals (ELDN) stake by 21% in Q1 2026, buying an estimated $1.78M and bringing the position to 4,382,245 shares worth $13.5M. The position accounts for ﹤0.01% of the portfolio, ranked #3311.

BlackRock first reported a position in ELDN in Q1 2015 and has held it in 45 quarters since. 121 funds tracked by Wall St. Rank hold ELDN as of Q1 2026.

  • BlackRock held 4,382,245 shares of Eledon Pharmaceuticals worth $13.5M as of Q1 2026.
  • BlackRock bought 755,037 Eledon Pharmaceuticals shares in Q1 2026, an estimated $1.78M.
  • Eledon Pharmaceuticals made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #3311 holding.
  • BlackRock first reported a position in Eledon Pharmaceuticals in Q1 2015 and has held it in 45 quarters since.
  • 121 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.